Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg ups target price on Wheaton Precious Metals

(Sharecast News) - Berenberg updated its model for Wheaton Precious Metals following its Q2 results last week, leading it to raise its target price on the stock from 7,200p to 7,800p. Berenberg said the company delivered record quarterly earnings and strong beats versus consensus, of 7% for adjusted earnings per share and 15% for operating cash flows, which were driven by a combination of higher production, sales volumes, realised prices and margins.

The German bank, which kept its 'buy' rating on the stock, noted that production guidance for 2025 was maintained, and that several near-term development streams were all progressing on track, and highlighted that execution of Wheaton's "compelling" expected 32% volume growth to 2028 was "a key facet" to achieving a continued re-rate higher.

Berenberg said its updated model had lifted its 2025 underlying earnings estimate by roughly 4% and earnings per share by about 3%. However, it also moderated its grade estimates at Wheaton's San Dimas asset in Mexico, which trimmed its 2027 earnings expectation. However, improved operating cash flows increased its end-2025 net-cash forecast by roughly 6%.

"As Wheaton has delivered consistent output from its high-quality baseline portfolio (capitalising on strong precious metals prices), and with its near-term growth projects all progressing on track, we have witnessed a multiple re-rate. We, therefore, lift our NAV multiple to 3x from 2.5x, reflecting a c10% premium to the average trading level since January 2025 of 2.75x (on our NAV estimate)," said Berenberg.

"We maintain our 30x EBITDA multiple, which reflects Wheaton's near-term volume growth trajectory. The shares are currently trading on 3x NAV and 28.3x 12-month forward EBITDA. Note that Wheaton's implied share price on 30x 2027E EBITDA is 8,700p. Further, if we run our model at spot gold and silver prices, our price target increases to 9,400p, representing c25% upside."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.